Week 4 Updates
Saren S -
Welcome back everyone!
This week, I’ve been diving into the complexities of insurance policies and how they impact the affordability of EpiPens. I initially thought insurance would make these life-saving devices accessible to most patients, but after researching different plans, I’ve realized that isn’t always the case. As part of my research, I’ve been analyzing how different insurance policies affect access to life-saving epinephrine auto-injectors. Many insurance companies categorize EpiPens as Tier 3 or non-preferred brand-name drugs, leading to higher copays and out-of-pocket costs. While generic versions are available, they can still be expensive, especially under high-deductible health plans (HDHPs), which require patients to pay the full price until they meet their deductible.
To better understand the real-world impact of these policies, I’ve been shadowing an allergist who regularly prescribes EpiPens. During my time in the clinic, I’ve seen firsthand how financial concerns influence patient decisions. Some families opt to take fewer EpiPens than recommended because of cost, which can be dangerous if an emergency occurs when their only auto-injector isn’t accessible. Others try to stretch expired EpiPens because they can’t afford replacements. It’s eye-opening to see how these financial burdens translate into real risks for patients.
In addition to insurance policies, I’ve also been researching copay assistance programs and manufacturer coupons, which can help offset costs. However, these programs aren’t always widely accessible, and many expire after a certain period, leaving patients without long-term solutions. Moving forward, I plan to analyze different insurance providers to identify which offer the best coverage for epinephrine auto-injectors. I also hope to speak with policymakers about potential solutions to improve accessibility for all patients, regardless of their financial situation.